Assessing ADMA Biologics (ADMA) Valuation After Its Upgraded 2025 Revenue Guidance

ADMA Biologics (ADMA) just lifted its 2025 revenue guidance to $510 million, up from its previous expectation of more than $500 million, a move that puts the company’s growth trajectory squarely in focus.

See our latest analysis for ADMA Biologics.

The upbeat guidance comes as momentum builds again in the stock, with a roughly 14% 1 month share price return and a standout 3 year total shareholder return above 430% reinforcing the growth narrative.

If this kind of biologics growth story has your attention, now may be a good time to explore other potential opportunities across healthcare stocks.

With shares already up sharply over three years and trading at a sizeable discount to analyst targets, the key question now is whether ADMA still offers mispriced upside or if the market is already factoring in its next leg of growth.

Most Popular Narrative: 28.1% Undervalued

With ADMA Biologics closing at $19.58 versus a narrative fair value of $27.25, the valuation case leans heavily on long term growth and margins.

The recent debt refinancing, lowering the cost of capital and providing a new $300 million credit facility, enhances liquidity and financial flexibility, supporting ongoing strategic growth initiatives and potentially improving future free cash flow and EPS.

Read the complete narrative.

Want to see what kind of multi year revenue climb and profit margins are baked into that fair value, and how rich a future earnings multiple it assumes? The full narrative reveals the detailed growth runway and valuation math driving that upside case.

Result: Fair Value of $27.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on scaling its yield enhancement process and avoiding major setbacks in its narrow IVIG portfolio, where competition and regulation could quickly bite.

Find out about the key risks to this ADMA Biologics narrative.

Build Your Own ADMA Biologics Narrative

If you want to challenge this view or dive into the numbers yourself, you can build a fresh, personalized take on ADMA in under three minutes: Do it your way.

A great starting point for your ADMA Biologics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Before you move on, put Simply Wall Street’s powerful screener to work so you do not miss the next opportunity hiding in plain sight.

• Capitalize on early stage growth potential with these 3633 penny stocks with strong financials that already show resilient balance sheets and improving fundamentals.
• Position yourself at the frontier of innovation through these 28 quantum computing stocks, targeting companies pushing real world applications in computation and security.
• Strengthen your portfolio’s income engine by focusing on these 12 dividend stocks with yields > 3% that combine attractive yields with sustainable payout ratios.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com